FOR IMMEDIATE RELEASE: August 27, 2024 The Multidisciplinary Association for Psychedelic Studies (MAPS) awarded Emory University researchers a $200,000 grant for a pilot study examining MDMA-assisted Massed Exposure Therapy for PTSD. The study is being conducted by Dr. Barbara Rothbaum and Dr. Jessica Maples-Keller at the Emory Healthcare Veterans Program in Atlanta, Georgia. Enrollment for ..read more

FOR IMMEDIATE RELEASE: August 9, 2024 Aug 9, 2024 – San Jose, CA – The Multidisciplinary Association for Psychedelic Studies (MAPS) is evaluating the path forward for safe, legal access to MDMA-assisted therapy following the announcement from Lykos Therapeutics that the potential approval of midomafetamine  (MDMA) capsules used in combination with therapy for PTSD will ..read more

Obituary for California SB1012 As we near the eve of perhaps MAPS’ biggest milestone in its 38th-year history – the FDA PDUFA date – we wanted to take a moment to reflect on another significant effort of the last few years. We have written and spoken in the past about efforts to reform psychedelic policy in California, where MAPS was physically based for many years, and where so many people and communities continue to carry a legacy of psychedelic activism forward. After two more legislative attempts at psychedelic policy change were thwarted in committee this year, we wanted to memorialize M ..read more

Richard Nixon announced the War on Drugs in 1971 and, in doing so, perpetuated an ongoing rhetoric and myth of Black criminality. Ronald Reagan escalated the impact of this policy by prioritizing punishment over treatment, thereby causing a significant increase in the incarcerated population, especially for nonviolent drug offenses.  Over a dozen organizations joined MAPS in sending letters to the United States Sentencing Commission, urging a review and revision of the Drug Quantity and Drug Conversion Tables. The United States is long overdue for sentencing reform, and the urgency lies e ..read more

Join us on Tuesday, July 16 to hear from MAPS leaders We’re excited to invite you to an exclusive webinar, “MAPS, MDMA & Beyond,” where you will have the opportunity to hear from leaders at MAPS about how we’re approaching this pivotal period following the FDA Advisory Committee hearing. As we, along with the entire psychedelic ecosystem, eagerly await the FDA’s decision on Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy for PTSD, this is a momentous time for all of us. Event Details: Date: Tuesday, July 16th Time: 4:00 pm PDT   Duration: 1 Hour Join MAPS ..read more

Dear Friends and Allies,  On June 4, 2024, the U.S. Food and Drug Administration (FDA) convened a meeting of the Psychopharmacologic Drugs Advisory Committee to evaluate Lykos Therapeutics’ (Lykos) New Drug Application (NDA) for MDMA-assisted therapy for PTSD. First and foremost, we applaud both the FDA and Lykos, MAPS’ former subsidiary, for their diligent efforts in preparation and presentation at the meeting. Lykos Therapeutics Statement on FDA Advisory Committee Meeting – Jun 13, 2024 Lykos Therapeutics Provides Update on FDA Advisory Committee Meeting for Investigational MDMA-Assist ..read more

The first half of 2024 has been riveting for a few reasons. By now, Oregon’s regulated access program has been in effect for eighteen months, with thousands of people having received psilocybin services; a rulemaking process is well underway in Colorado while the state simultaneously adjusts to decriminalization of multiple sacred plants; and technical lessons learned from past policy efforts – successful or not – are beginning to be implemented in new proposals across the country.  While many watch the rollercoaster leading up to FDA’s decision about Lykos’ application seeking approval o ..read more

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Momentum Events are pleased to announce the successful conclusion of their professional collaboration following the groundbreaking Psychedelic Science 2023 conference. The event, held in Denver, Colorado, marked a historic milestone as the largest psychedelic conference in history, bringing together experts, researchers, and enthusiasts from around the world to discuss the latest advancements and insights in the field of psychedelics. As the producer of Psychedelic Science 2023, Momentum played a pivotal role in orchestrating ..read more

The post Making the Invisible Visible appeared first on Multidisciplinary Association for Psychedelic Studies - MAPS ..read more

The post Psychedelics & Migration: Healing Intergenerational Trauma Across Cultures appeared first on Multidisciplinary Association for Psychedelic Studies - MAPS ..read more